CR11243A - HUMAN ANTIBODIES AGAINST HUMAN CD20 AND METHOD FOR USE - Google Patents

HUMAN ANTIBODIES AGAINST HUMAN CD20 AND METHOD FOR USE

Info

Publication number
CR11243A
CR11243A CR11243A CR11243A CR11243A CR 11243 A CR11243 A CR 11243A CR 11243 A CR11243 A CR 11243A CR 11243 A CR11243 A CR 11243A CR 11243 A CR11243 A CR 11243A
Authority
CR
Costa Rica
Prior art keywords
human
antibodies against
antibody
human antibodies
against human
Prior art date
Application number
CR11243A
Other languages
Spanish (es)
Inventor
Joel Martin
Li-Hsien Wang
Sean Stevens
Erin Allison
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CR11243A publication Critical patent/CR11243A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Un anticuerpo humano o un fragmento de union al antigeno de un anticuerpo que se une especificamente al CD20 humano que es capaz de inducir una citotoxicidad dependiente del complemento (CDC), y que es capaz de aumentar el tiempo de supervivencia sin sintomas entre aproximadamente 2 veces a aproximadamente 9 veces mas o mayor, con relacion a animales control tratados en un modelo de raton del linfoma humano.A human antibody or an antigen binding fragment of an antibody that specifically binds to human CD20 that is capable of inducing complement-dependent cytotoxicity (CDC), and that is capable of increasing the survival time without symptoms by approximately 2 times at about 9 times or more, in relation to control animals treated in a mouse model of human lymphoma.

CR11243A 2007-07-31 2010-01-28 HUMAN ANTIBODIES AGAINST HUMAN CD20 AND METHOD FOR USE CR11243A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96281107P 2007-07-31 2007-07-31
US6799408P 2008-03-03 2008-03-03

Publications (1)

Publication Number Publication Date
CR11243A true CR11243A (en) 2010-05-19

Family

ID=40010730

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11243A CR11243A (en) 2007-07-31 2010-01-28 HUMAN ANTIBODIES AGAINST HUMAN CD20 AND METHOD FOR USE

Country Status (29)

Country Link
US (3) US7879984B2 (en)
EP (1) EP2178916B1 (en)
JP (1) JP5588865B2 (en)
KR (1) KR101561020B1 (en)
CN (1) CN101809037B (en)
AU (1) AU2008282152B2 (en)
BR (1) BRPI0813985B1 (en)
CA (1) CA2695199C (en)
CO (1) CO6260105A2 (en)
CR (1) CR11243A (en)
DK (1) DK2178916T3 (en)
DO (1) DOP2010000037A (en)
EC (1) ECSP10010005A (en)
ES (1) ES2527297T3 (en)
GT (1) GT201000026A (en)
HK (1) HK1141811A1 (en)
HN (1) HN2010000202A (en)
MA (1) MA31634B1 (en)
ME (1) ME00973B (en)
MX (1) MX2010000970A (en)
MY (1) MY147651A (en)
NI (1) NI201000016A (en)
NZ (1) NZ583019A (en)
PL (1) PL2178916T3 (en)
RU (1) RU2486205C2 (en)
SV (1) SV2010003468A (en)
TN (2) TN2010000054A1 (en)
WO (1) WO2009018411A1 (en)
ZA (1) ZA201000545B (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
HUE055817T2 (en) 2009-07-08 2021-12-28 Kymab Ltd Animal models and therapeutic molecules
KR101862277B1 (en) 2009-12-21 2018-06-01 리제너론 파마슈티칼스 인코포레이티드 HUMANIZED FcγR MICE
CN103945689B (en) 2011-09-19 2016-10-19 科马布有限公司 The multifarious manipulation of immunoglobulin gene and multispecific antibody therapeutic agent
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
EP2812443B1 (en) 2012-02-06 2019-05-29 Inhibrx, Inc. Cd47 antibodies and methods of use thereof
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
TWI745610B (en) * 2012-11-14 2021-11-11 美商再生元醫藥公司 Recombinant cell surface capture proteins
US20140140991A1 (en) * 2012-11-20 2014-05-22 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with bruton's tyrosine kinase
MX2015009952A (en) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Erk inhibitors and uses thereof.
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
TW201526897A (en) 2013-04-17 2015-07-16 Signal Pharm Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2014179661A1 (en) 2013-05-03 2014-11-06 Celgene Corporation Methods for treating cancer using combination therapy
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
CA2926893C (en) * 2013-11-07 2022-04-12 F. Hoffmann-La Roche Ag Combination therapy of an anti cd20 antibody with a btk inhibitor
TWI754319B (en) 2014-03-19 2022-02-01 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
KR102614189B1 (en) 2014-11-17 2023-12-18 리제너론 파아마슈티컬스, 인크. Methods for tumor treatment using cd3xcd20 bispecific antibody
EP3660035A1 (en) 2015-05-30 2020-06-03 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
CA2985718A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
TW202340452A (en) 2015-08-04 2023-10-16 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
PE20231655A1 (en) 2015-10-02 2023-10-17 Hoffmann La Roche BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE
FI3394103T3 (en) 2015-12-22 2023-08-30 Regeneron Pharma Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
JP2019530641A (en) * 2016-07-19 2019-10-24 アイベントラス・インコーポレイテッドＩｂｅｎｔｒｕｓ，Ｉｎｃ． Bispecific protein and method for producing the same
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018118754A1 (en) * 2016-12-19 2018-06-28 Vanderbilt University Antibodies to human respiratory syncytial virus protein pre-fusion conformation and methods of use therefor
CN108395482B (en) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CA3067847A1 (en) 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
US20190194298A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
EA202091689A1 (en) 2018-01-31 2020-10-22 Ридженерон Фармасьютикалз, Инк. SYSTEM AND METHOD FOR DETERMINING THE CHARACTERISTICS OF IMPURITIES PRESENTING VARIANTS DIFFERENT IN SIZE AND CHARGE IN A PRODUCT PRESENTING A MEDICINAL
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
TW202311746A (en) 2018-02-02 2023-03-16 美商再生元醫藥公司 System and method for characterizing protein dimerization
JP2021514609A (en) 2018-02-28 2021-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Systems and methods for identifying viral contaminants
KR102503356B1 (en) 2018-03-19 2023-02-24 리제너론 파마슈티칼스 인코포레이티드 Microchip Capillary Electrophoresis Assay and Reagents
TW202016125A (en) 2018-05-10 2020-05-01 美商再生元醫藥公司 Systems and methods for quantifying and modifying protein viscosity
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN112218877A (en) 2018-08-27 2021-01-12 瑞泽恩制药公司 Application of Raman spectroscopy in downstream purification
TW202024639A (en) 2018-08-30 2020-07-01 美商再生元醫藥公司 Methods for characterizing protein complexes
US11590223B2 (en) 2018-08-31 2023-02-28 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
AU2019344795A1 (en) 2018-09-17 2021-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors targeting CD19 and CD20 and their uses
CA3115139A1 (en) 2018-10-01 2020-04-09 Adicet Bio Inc. Compositions and methods regarding engineered and non-engineered .gamma..delta.-t cells for treatment of hematological tumors
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
ES2942024T3 (en) 2019-01-16 2023-05-29 Regeneron Pharma Methods to characterize disulfide bonds
CN113785203A (en) 2019-05-13 2021-12-10 里珍纳龙药品有限公司 Improved competitive ligand binding assays
KR20220066393A (en) 2019-09-24 2022-05-24 리제너론 파아마슈티컬스, 인크. Systems and methods for the use and regeneration of chromatography
AU2020394428A1 (en) 2019-11-25 2022-07-14 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CN115666704A (en) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 Ingestible device for delivery of therapeutic agents to the gastrointestinal tract
US11835527B2 (en) 2020-01-21 2023-12-05 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
MX2023002417A (en) 2020-08-31 2023-03-22 Regeneron Pharma Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants.
MX2023006077A (en) 2020-11-25 2023-06-06 Regeneron Pharma Sustained release formulations using non-aqueous membrane emulsification.
CA3205135A1 (en) 2020-12-17 2022-06-23 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
EP4281542A1 (en) 2021-01-20 2023-11-29 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
IL305156A (en) 2021-03-03 2023-10-01 Regeneron Pharma Systems and methods for quantifying and modifying protein viscosity
US20240165153A1 (en) 2021-03-24 2024-05-23 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
MX2023010794A (en) 2021-03-26 2023-10-25 Regeneron Pharma Methods and systems for developing mixing protocols.
WO2022256383A1 (en) 2021-06-01 2022-12-08 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
IL311527A (en) 2021-09-20 2024-05-01 Regeneron Pharma Methods of controlling antibody heterogeneity
US20230110811A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. pH METER CALIBRATION AND CORRECTION
AU2022360838A1 (en) 2021-10-07 2024-03-28 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
EP4423018A1 (en) 2021-10-26 2024-09-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
WO2023177836A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2024130048A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
US20240255519A1 (en) 2023-02-01 2024-08-01 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
US20240285762A1 (en) 2023-02-28 2024-08-29 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
CN1320044A (en) 1998-08-11 2001-10-31 Idec药物公司 Combination therapies for B-cell lymphomas comprising administration of anti-CD 20 antibody
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP1642596A3 (en) 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
ITMI991299A1 (en) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche USE OF ANTIBODIES AGAINST SURFACE ANTIGENS FOR THE TREATMENT OF DISEASE TRANSPLANT AGAINST GUESTS
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN101914158A (en) 2002-02-14 2010-12-15 免疫医疗公司 Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20030233797A1 (en) * 2002-06-25 2003-12-25 Anderson Dean A. Air handling system including shroud and grille, and method of use
CN101928344B (en) * 2002-10-17 2014-08-13 根马布股份公司 Human monoclonal antibodies against cd20
US6736137B1 (en) * 2003-02-28 2004-05-18 Tmr-A, Llc Protective hooded respirator with oral-nasal cup breathing interface
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
EP1626993B1 (en) 2003-05-09 2015-03-11 Duke University Cd20-specific antibodies and methods of employing same
AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 UNION MOLECULES
DE10334793A1 (en) * 2003-07-30 2005-02-24 BSH Bosch und Siemens Hausgeräte GmbH Drying items in domestic dish washing machines has reversible hydroscopic material filled column through which recirculated air is driven by fan
WO2005023302A2 (en) 2003-08-29 2005-03-17 Genentech, Inc. Anti-cd20 therapy of ocular disorders
AU2004303848A1 (en) 2003-12-19 2005-07-07 Genentech, Inc. Detection of CD20 in transplant rejection
JP5848861B2 (en) * 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Human monoclonal antibody against CD20
EP1773393A2 (en) 2004-05-05 2007-04-18 Genentech, Inc. Preventing autoimmune disease by using an anti-cd20 antibody
SV2006002131A (en) 2004-06-04 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF LUPUS
CN101087807A (en) 2004-10-05 2007-12-12 健泰科生物技术公司 Method for treating vasculitis
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
CN1331888C (en) * 2005-03-02 2007-08-15 中国人民解放军军事医学科学院生物工程研究所 Single strand double specificity anti-body resisting human B cell leucoma
AR053579A1 (en) 2005-04-15 2007-05-09 Genentech Inc TREATMENT OF INTESTINAL INFLAMMATORY DISEASE (IBD)
RU2007143302A (en) 2005-04-22 2009-05-27 Дженентек, Инк. (Us) METHOD FOR TREATING DEMENTIA OR ALZHEIMER'S DISEASE ANTIBODIES TO CD20
JP2008541758A (en) 2005-06-02 2008-11-27 アストラゼネカ エービー Antibodies against CD20 and uses thereof

Also Published As

Publication number Publication date
US8329181B2 (en) 2012-12-11
DOP2010000037A (en) 2017-07-31
KR20100057012A (en) 2010-05-28
MA31634B1 (en) 2010-08-02
TN2010000056A1 (en) 2011-09-26
SV2010003468A (en) 2010-08-10
JP2010535033A (en) 2010-11-18
US8097713B2 (en) 2012-01-17
AU2008282152A1 (en) 2009-02-05
ME00973B (en) 2012-06-20
ZA201000545B (en) 2011-04-28
BRPI0813985A2 (en) 2017-08-01
ES2527297T3 (en) 2015-01-22
WO2009018411A1 (en) 2009-02-05
EP2178916B1 (en) 2014-12-17
US7879984B2 (en) 2011-02-01
EP2178916A1 (en) 2010-04-28
CN101809037A (en) 2010-08-18
CO6260105A2 (en) 2011-03-22
MX2010000970A (en) 2010-03-09
JP5588865B2 (en) 2014-09-10
AU2008282152B2 (en) 2013-12-19
HK1141811A1 (en) 2010-11-19
NZ583019A (en) 2011-05-27
NI201000016A (en) 2010-07-27
US20120100145A1 (en) 2012-04-26
KR101561020B1 (en) 2015-10-26
CA2695199C (en) 2016-07-19
HN2010000202A (en) 2012-08-15
TN2010000054A1 (en) 2011-09-26
RU2486205C2 (en) 2013-06-27
PL2178916T3 (en) 2015-08-31
RU2010107175A (en) 2011-09-10
CA2695199A1 (en) 2009-02-05
US20090035322A1 (en) 2009-02-05
BRPI0813985B1 (en) 2022-05-10
US20110081681A1 (en) 2011-04-07
GT201000026A (en) 2012-04-23
ECSP10010005A (en) 2010-03-31
MY147651A (en) 2012-12-31
DK2178916T3 (en) 2015-01-12
CN101809037B (en) 2014-01-15

Similar Documents

Publication Publication Date Title
CR11243A (en) HUMAN ANTIBODIES AGAINST HUMAN CD20 AND METHOD FOR USE
PE20181399A1 (en) ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION
AR068818A1 (en) COMBINATION THERAPY WITH ANTI-CD20, TYPE I AND TYPE II ANTIBODIES FOR THE TREATMENT OF CANCER, USE, KIT
GT200900002A (en) ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER
AR110676A1 (en) TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
AR074360A1 (en) MONOCLONAL ANTIBODY OR FRAGMENT OF UNION TO ANTIGEN OF THE SAME PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION
CL2008003788A1 (en) Pharmaceutical composition comprising a) the humanized b-ly1 antibody (anti-cd20 / human b-lymphocyte / bp35 restricted referencing antigen, type ii), b) optionally from 0.001% to 1% w / v of at least one surfactant, and c) 1 to 100 mm of a buffer; use to treat cd20-related diseases.
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE
MY189692A (en) Anti-ox40 antibodies and methods of use thereof
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
PA8782201A1 (en) HUMANIZED ANTIBODY AGAINST AB GLOBULOMER (20-42) AND ITS USES
NI200900115A (en) HUMAN ANTIBODIES AGAINST HUMAN DELTA TYPE LIGAND 4.
UY33407A (en) SPECIFIC ANTIBODIES OF THE HUMAN GDF8 FACTOR
CY1116488T1 (en) ANTI-PERPETIN antibodies
BR112013029330A8 (en) maytansinoid anti-cd19 immunoconjugate antibody for treatment of B-cell disease symptoms
CL2007002800A1 (en) ANTI-RECEIVER MONOCLONAL ANTIBODY OF INTERLEUCINE 17 (IL-17RA) OR FRAGMENT OF ANTIGEN UNION OF THE SAME; POLINUCLEOTIDE THAT CODIFIES IT; PREPARATION METHOD; AND METHOD TO TREAT A DISORDER INFLUENCED BY THE ACTIVATION OF IL-17RA.
PE20120551A1 (en) ANTIBODIES AGAINST HUMAN ANGIOPOYETIN 2
BR112012022214A2 (en) methods and compositions for treating degum disease
ATE502052T1 (en) MONOCLONAL ANTIBODIES TO THE HUMAN ANTI-MÜLLERIAN HORMONE RECEPTOR TYPE II (AMHR-II)
MX2019011624A (en) Methods and compositions for reduction of immunogenicity.
CY1118918T1 (en) B cell extinction agents, such as ENANTI-CD20 antibodies or their fragments for the treatment of chronic fatigue syndrome
EA201891499A1 (en) CHEMICAL DOG ANTI-CD20 ANTIBODY
AR107893A1 (en) COMBINED THERAPIES, COMBINATION OF A BACE INHIBITOR AND AN ANTIBODY OR AN ANTIGEN FRAGMENT FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH B AMYLOID ACCUMULATION
AR086984A1 (en) ANTI-CXCR4 ANTIBODY WITH EFFECTIVE FUNCTIONS AND ITS USE IN CANCER TREATMENT